Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-101 plus adalimumab in moderate to severe ulcerative colitis
NL-OMON51097Phase 2Active, not recruiting
- Sponsor
- Applied Molecular Transport
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing AMT-101 + adalimumab with Placebo + adalimumab (2 arms). Primary endpoints: Mean change in UC-100 score from baseline, Mean change in Robarts Histopathology Index from baseline and 15 more. Started Jun 2021; status: active, not recruiting.
02
Drugs
AMT-101adalimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON51097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51097.